Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus

Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO · May 17, 2023

Keywords

ClinConnect Summary

This clinical trial is looking into the long-term effects of COVID-19, specifically focusing on how the virus might lead to diabetes in patients who were hospitalized with severe cases. Researchers have found that these patients are more likely to develop insulin resistance (where the body doesn’t use insulin properly), glucose intolerance (which can lead to prediabetes), and even type 2 diabetes compared to those who had milder cases or did not have COVID-19 at all. The goal is to better understand these risks and how they can affect health in the long run.

To participate in this study, you need to be between 65 and 74 years old and have a body mass index (BMI) below 40, which is a measure of body weight in relation to height. However, if you had diabetes before getting COVID-19, took diabetes medications prior to your infection, or have had a heart attack or stroke recently, you wouldn’t be eligible to join the trial. Participants will undergo long-term follow-up assessments to monitor their health and any potential development of diabetes. This study is important as it aims to gather more information that could help in managing health after COVID-19 and improving care for those at risk of diabetes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Body Mass index (BMI) \< 40 kg/m2
• Exclusion Criteria:
• • History of diabetes prior to SARS-CoV-2 infection
• • Took medications used to treat diabetes prior to SARS-CoV-2 infection
• • History of myocardial infarction or stroke within 6 months
• • History of major organ system disease prior to COVID-19 infection